The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 8 July, become the first regulator in the world to approve elinzanetant (Lynkuet) for the treatment of moderate to severe vasomotor symptoms (hot flushes) associated with the menopause.
Similar Posts
Sir David Spiegelhalter: Regulation in an age of personalised medicine
The internationally renowned expert in the calculation and communication of risk and statistics, Sir David Spiegelhalter, discusses the concept of a ‘preference zone’ to frame the demands of safety, efficacy and choice in the era of personalised medicine.
Guidance: Timelines for acceptance of CE marked medical devices in Great Britain (GB)
Transitional arrangements and timelines for acceptance of CE marked medical device in Great Britain.
Field Safety Notices: 16-20 February 2026
List of Field Safety Notices: 16-20 February 2026
Corporate report: Human Medicines Regulations 2012 Advisory Bodies Annual Report 2024
Annual Report of the Human Medicines Regulations 2012 Advisory Bodies – the Commission on Human Medicines (CHM) and the British Pharmacopoeia Commission.
Decision: Advertising Investigations: October 2025
Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
Consultation on the International Council for Harmonisation (ICH) E21 Guideline on the Inclusion of Pregnant and Breast-feeding Individuals in Clinical Trials
The MHRA is consulting with UK stakeholders to gather feedback and comments on a new international guideline for the appropriate inclusion and/or retention of pregnant and/or breast-feeding individuals in clinical trials of medicines.